SOURCE: International Stem Cell Corp.

International Stem Cell Corp.

November 18, 2013 07:30 ET

International Stem Cell Corp. CEO Featured in Exclusive QualityStocks Interview

SCOTTSDALE, AZ--(Marketwired - Nov 18, 2013) - QualityStocks today announces that a new audio interview with International Stem Cell Corp. (OTCQB: ISCO) Executive Vice President Dr. Simon Craw is now available. The interview can be heard at

International Stem Cell Corp. specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. ISCO has a strong patent portfolio offering clean intellectual property and was the first to develop and perfect a new class of human stem cells created from unfertilized human eggs through the company's patented process.

After highlighting his own extensive background as a scientist in the life science industry, Dr. Craw provides information on the company's CEO Professor Andrew Semechkin, a Russian Academy of Science member and internationally recognized scientist and business man.

Dr. Craw then explains considerable advances in the company's Parkinson's disease program, for which ISCO has carried out several stem cell-based experiments and recently concluded its first pilot primate study with favorable results.

"On the research and development side, the most significant achievements we've made this year are really in our Parkinson's disease program ..." says Dr. Craw. "This study was very very important for us to demonstrate that the symptoms of Parkinson's can be alleviated using a stem cell therapy and it's a precursor to any human studies that we would want to carry out."

ISCO in mid-2104 plans to submit to the U.S. FDA an investigational new drug (IND) application, and recently engaged Duke University as a partner to carry out the phase I clinical study of Parkinson's disease in human subjects. 

Dr. Craw gives an in-depth explanation of the company's core technology, demonstrating how the company's stem cells are clinically superior in their ability to differentiate into other cells to treat millions of individuals without restriction, and how they bypass ethical controversy of embryonic stem cells. 

"What we have at International Stem Cells is a proprietary stem cell platform that is unique and differentiated and actually offers substantial benefits over other stem cell platforms that are out there," he says.

Dr. Craw also offers an outlook on the company's goals for the remainder of 2013, including:

  • Grow full-year 2013 revenue by approximately 20 percent over 2012
  • Launching new products through subsidiary companies
  • Filing submission with the FDA to request a pre-IND meeting to discuss a plan for the clinical trials
  • Publishing results of its primate model study in peer-reviewed scientific journals

Looking beyond 2013, the company anticipates starting its phase 1 clinical trials in the middle of next year, representing a significant achievement for ISCO and individuals with the disease.

"That will be a very important milestone not just for the company but for everyone who suffers from this debilitating disease. We'll be the first company in the world that will be taking a stem-cell based product from a pluripotent stem cell platform and using it to treat people with this disease," Dr. Craw says in conclusion.

About International Stem Cell Corp.

International Stem Cell Corp. is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care (

For more information visit

For more information on International Stem Cell Corp., visit: 

About QualityStocks

Small Cap Stock Newsletter QualityStocks is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one free Daily Newsletter Report. QualityStocks also utilizes social media and networking to maintain constant communication with its rapidly growing audience. To date, QualityStocks has more than one million users following various social networking accounts.

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

The QualityStocks Blog

The QualityStocks Blog keeps investors up to date on everything related to the Small-Cap and Micro-Cap markets. Alternative fuels and power sources, entertainment media, telecommunications, delivery services, healthcare, and retail are all covered on a regular basis. By visiting our blog, investors also discover emerging companies that they otherwise would not have heard about. To date, more than 20,000 articles have been published via the QualityStocks Blog.

The QualityStocks Message Boards

The message board here at QualityStocks is one of the most highly regulated, no-nonsense forums online today; an uncommon haven of highly relevant, SPAM-free investor interaction. Unlike the majority of boards currently in operation, you won't find pumping, bashing, advertising, or malicious posting of any kind here. The QualityStocks Message Boards has over 34,000 registered users.

The QualityStocks Daily Newsletter

With all of the stock picks and recommendations available today in the investment world, selecting and deciding on the right stocks can be tedious and time consuming. At QualityStocks, we collate hundreds of investment newsletters into The ONE and ONLY "The QualityStocks Daily", featuring a summary format in which you can view the latest stock picks EVERYDAY.


Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Contact Information